Pulmonary fibrosis affects roughly 30 to 97 out of every 100,000 people in the United States, depending on how broadly the condition is defined. That translates to an estimated 100,000 or more Americans living with the idiopathic form alone, the most common and severe type. While it’s not as widespread as conditions like asthma or COPD, the numbers have been climbing steadily, and the disease carries serious consequences for those diagnosed.
U.S. Prevalence and Incidence
The most detailed recent data comes from a study published in CHEST covering 2017 to 2022. Researchers found that the adjusted prevalence of idiopathic pulmonary fibrosis (IPF) ranged from about 33 to 67 per 100,000 people. Using a broader diagnostic definition, the crude prevalence climbed from 37.5 per 100,000 in 2017 to 96.2 per 100,000 by 2022.
That rising prevalence doesn’t necessarily mean more people are developing the disease each year. Incidence rates, which measure new diagnoses, stayed fairly stable at roughly 9 to 18 new cases per 100,000 person-years throughout the same period. The growing prevalence likely reflects improved detection and the fact that people with pulmonary fibrosis are living somewhat longer thanks to newer treatments, so more diagnosed patients are alive at any given time.
How Rates Compare Globally
North America has the highest reported prevalence of pulmonary fibrosis in the world, with adjusted estimates of 24 to 30 per 10,000 people. Europe trails behind, with estimates ranging from about 0.33 to 2.51 per 10,000. Some of that gap is real, but much of it reflects differences in how aggressively the disease is screened for and how medical records are coded.
Global mortality from the disease has been gradually increasing. The crude death rate rose from about 2.1 per 100,000 in 2001 to 3.1 per 100,000 by 2022. In the Americas, the age-adjusted mortality rate in 2022 was 1.80 per 100,000, compared to 1.11 in Europe and 1.21 in the Western Pacific region. South America saw the steepest increase over two decades, while North American death rates held relatively steady.
Who Gets Pulmonary Fibrosis
Pulmonary fibrosis overwhelmingly affects older adults. The median age at diagnosis is 75 years, and the disease is rare before age 50. Men are diagnosed about twice as often as women. In a large UK registry of over 7,000 IPF cases, nearly 78% were male.
The reasons for the sex difference aren’t entirely clear. Hormonal factors, higher rates of occupational dust and fume exposure among men, and historically higher smoking rates in men all likely play a role. The CDC reports that among the roughly 67,800 Americans who died with IPF between 2020 and 2022, 59% were male and 41% were female, suggesting the gap may be narrowing somewhat compared to older data.
Pulmonary Fibrosis Linked to Other Conditions
IPF, where no clear cause is found, is the most well-known form of pulmonary fibrosis. But lung scarring also develops as a complication of several autoimmune and connective tissue diseases, and in some of these conditions it’s surprisingly common.
- Mixed connective tissue disease: about 56% of patients develop lung involvement
- Systemic sclerosis (scleroderma): roughly 47%
- Inflammatory myositis: around 41%
- Sjögren syndrome: 10% to 20%, depending on how it’s detected
- Rheumatoid arthritis: approximately 11% to 20%
- Lupus: about 6%
These autoimmune-related forms of pulmonary fibrosis sometimes respond differently to treatment than IPF, and they can progress at very different speeds. People with these conditions are typically monitored for early signs of lung scarring through periodic breathing tests and imaging.
Diagnostic Delays Are Common
One reason prevalence figures may undercount the true burden of pulmonary fibrosis is that the disease is frequently missed or misdiagnosed in its early stages. The hallmark symptoms, a dry cough and gradual shortness of breath, mimic dozens of more common conditions like asthma, heart failure, or simple deconditioning from aging.
Studies show the median delay between the onset of symptoms and a confirmed diagnosis is about 2 years, with some patients waiting 5 years or longer. During that time, patients often see multiple physicians and receive incorrect diagnoses. This delay isn’t just frustrating. Research published in BMJ Open Respiratory Research found that longer diagnostic delays are associated with worse lung function at the time of diagnosis, more hospitalizations, and lower quality of life. Since available treatments work by slowing further scarring rather than reversing it, every month of delay represents lung function that can’t be recovered.
Survival and Prognosis
IPF carries a median survival of 3 to 5 years after diagnosis, making it more lethal than many cancers. The annualized age-adjusted death rate in the U.S. is 7.1 per 100,000 people, based on CDC data from 2020 to 2022. That figure accounts for nearly 68,000 deaths over those three years.
Two approved medications can slow the rate of lung function decline, but they come at a steep cost. Anti-fibrotic drugs run more than $110,000 per year, compared to about $12,300 annually for symptom management alone. A U.S. cost-effectiveness analysis found that neither medication met standard thresholds for cost-effectiveness, averaging $1.6 million to gain one additional quality-adjusted life year over symptom management. For many patients, the practical reality involves balancing the potential to slow progression against significant out-of-pocket expenses, side effects, and the limited impact these drugs have on day-to-day symptoms.
Survival varies widely depending on how early the disease is caught, how quickly it progresses, and whether the patient is a candidate for lung transplant. Some people live well beyond the median, particularly those diagnosed with mild disease. Others experience rapid decline within months. Non-IPF forms of pulmonary fibrosis, especially those tied to autoimmune conditions, sometimes follow a slower and more variable course.